All News
The Need for Comparative Treatment Trials in Psoriatic Arthritis
Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. While this is a very welcome development in a disease which has had less treatment options compared to RA, it leaves us with a difficult conundrum: which agent to choose for an individual patient.
Read Article
⭐️Ustekinumab+MTX vs. UST+PBO in PsA?
➡️Additional MTX has no positive impact on UST efficacy for arthritis, enthesitis, dactylitis, skin, QoL, & function.
*️⃣Thus, no evident to add or maintain ongoing MTX when starting UST
Late-Breaking Poster#12. #ACR21 @RheumNow #ACRBest https://t.co/k96PPUtwct
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #ustekinumab loses throne in #psoriasis and #psoriatic arthritis except maybe if concomitant inflammatory bowel disease post TNFi? Rapidly evolving PsA Rx. Abst#1773 #ACR21 @RheumNow https://t.co/Dkf2DFFsSK
Janet Pope Janetbirdope ( View Tweet)
So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different w or without #MTX. Abst#L12 @RheumNow #ACR21 https://t.co/Zp5owTpLvm
Janet Pope Janetbirdope ( View Tweet)
Methotrexate did not improve Ustekinumab efficacy in tx of PsA
⭐️Addition of MTX did not improve dactylitis, enthesitis, skin, QoL or function
#ACR21 #ACRBest @RheumNow
Abs#L12
https://t.co/6dxWPNskou https://t.co/BnzH8PfaMV
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Phase 2 trial of tildrakizumab (IL-23i) for the treatment of PsA showed lower efficacy in pts with metabolic syndrome compared to those without
#ACR21 @RheumNow
Abs#1819
https://t.co/GYHbiH9NSW https://t.co/YGcZcITjzj
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
2 year study shows low rates of radiographic progression in PsA pts on guselkumab
#ACR21 @RheumNow Abs#1805
https://t.co/dobg3cEXXG https://t.co/m1P24qPAhy
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Abst1773 #ACR21 @rheumnow guselkumab outperforms ustekinumab in both msk & skin domains in bio naive & bio experienced alike- data from pivotal Phase III trials : at weeks 52 GUS better ACR20, PASI100 in both doses vs Stelara https://t.co/lfddaCJA5O
Olga Petryna DrPetryna ( View Tweet)
No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthritis, enthesitis, dactylitis, skin, QoL or function. Abstr#L12 #ACR21 @RheumNow https://t.co/iojKLqRb06
Richard Conway RichardPAConway ( View Tweet)
Individual patient data analysis from RCTs (indirect comparison) of guselkumab vs ustekinumab in PsA. Guselkumab appears superior for joint and skin. Abstr#1773 #ACR21 @RheumNow https://t.co/MTRjXyHoh6
Richard Conway RichardPAConway ( View Tweet)
Guselkumab 100 mg Q4W and Q8W provided robust and sustained benefits to patients with active PsA across multiple domains. Listen to my interview with Prof. Laura Coates on this and other emerging treatments in PsA here https://t.co/PSbJ0HA5a6
@RheumNow #ACR21 Abstr#1335 https://t.co/WzBOYGOxAA
Dr. Antoni Chan synovialjoints ( View Tweet)
Supporting date for Ixekizumab in PsA with symptoms of axial involvement.
🔹Improvement in QoL (SF-36), ASDAS, BASDAI50
🔹Maintained at 52 weeks
🔹Stricter criteria (younger, ⬆️CRP) showed similar results
https://t.co/QSJLQTxLcW
#ACR21 Abst#3147
@RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg
Richard Conway RichardPAConway ( View Tweet)
Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC )
#ACR21
https://t.co/0zskkywWu1 https://t.co/n3qs19rQNG
Links:
Dr. John Cush RheumNow ( View Tweet)
Guselkumab treatment of PsA improved Hgb levels and ⬇️ incidence of anemia
⭐️Anemia resolution associated with improved clinical status
#ACR21
#ACRBest
Abs#1331
@RheumNow
https://t.co/nbG7DpMDaR https://t.co/rxWsVfNqed
Robert B Chao, MD doctorRBC ( View Tweet)
Low incidence of GI-related serious AE in pooled 1 year data from VOY1&2 and DISC1&2 trials of Guselkumab for PsA/PsO treatment
⭐️no new onset IBD or exacerbation of IBD
⭐️no uveitis, infections, TB
Abs#1342
#ACR21
@RheumNow
https://t.co/x3OmLgInV0
Robert B Chao, MD doctorRBC ( View Tweet)
SEC demonstrated significantly longer time to flare vs PBO w/ sustained improvement of ERA and JPsA signs and symptoms up to Wk 104. No new safety signals. Plenary Abs 1424 #ACR21 #RheumNow @RheumNow https://t.co/VF2HmJ3Ha9 https://t.co/ApYFusADHX
Dr. Rachel Tate uptoTate ( View Tweet)
Abst1424 #ACR2021 @RheumNow study of SEC in children w/ERA or JPsA : 72% reduced flare risk. Improved JADAS-27 score in both the ERA and JPsA categories. ⬇️ disease activity, enthesitis count & joints with active arthritis. adverse events & serious AEs in the SEC & PBO comparable https://t.co/J4MdxeYxWZ
Olga Petryna DrPetryna ( View Tweet)
Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect. Anaemia resolution associated good outcomes, but many with good outcomes still anaemic. Abstr#1331 #ACR21 @RheumNow https://t.co/LL63Qc0nk5
Richard Conway RichardPAConway ( View Tweet)
Guselkumab (IL23p19 inhibitor) positive effect on axial outcomes in PsA, durable response across 2 years. Abstr#1330 #ACR21 @RheumNow https://t.co/8LOSdzCvRc
Richard Conway RichardPAConway ( View Tweet)
